Non-Small Cell Lung Cancer NSCLC
Conditions
Interventions
Observation group:None
Sponsors
Shaoxing People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Eligibility criteria: 1. Age from 18 to 75 years old, regardless of gender; 2. KPS score >=70; Life expectancy >=12 weeks; 3. Histologically or cytologically confirmed stage IIIB-IV NSCLC with negative driver genes; 4. No previous anti-tumor therapy; 5. Basically normal cardiac function (echocardiography showed left ventricular ejection fraction >50%); 6. Meet the basic requirements of chemotherapy, including no obvious abnormalities in bone marrow hematopoietic function, heart, liver and kidney function, and no unhealed trauma on the body. Blood routine: WBC>=3.5×10^9/L, PLT>=80×10^9/L, Hb>=90g/L. Renal function: Cr<=1.5×UNL (upper limit of normal). Liver function: BIL<=1.5×UNL, ALT/AST<=2.5×UNL. 7. Fully understand the study, voluntarily participate in the study, meet the conditions of follow-up and sign the informed consent;
Exclusion criteria
Exclusion criteria: 1. Poor image quality, affecting quantification; 2. Positive driver gene mutations; 3. Existing severe uncontrolled acute infection, or suppurative or chronic infection with prolonged wound healing; 4. Patients with pre-existing severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmia, unstable angina pectoris, myocardial infarction, severe heart valve disease, and resistant hypertension; 5. Suffering from uncontrollable mental or neurological diseases or mental disorders, poor compliance, and unable to cooperate in filling out the quality of life scale; Patients with obvious intracranial hypertension or neuropsychiatric symptoms; 6. Concomitant with other malignant tumors requiring active treatment; 7. Other circumstances considered by the investigator to be inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate(DCR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS);Overall Survival (OS);Immune and chemotherapy-related toxicity; | — |
Countries
China
Contacts
Public ContactXiaoling Zhu
Shaoxing People's Hospital
Outcome results
None listed